C3N-03080
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 67.99178645
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- MYC_TARGETS_V2+0.560
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.470
- SPERMATOGENESIS+0.320
- ALLOGRAFT_REJECTION+0.280
- PANCREAS_BETA_CELLS+0.280
- OXIDATIVE_PHOSPHORYLATION+0.160
- MITOTIC_SPINDLE+0.150
- KRAS_SIGNALING_DN+0.060
Top 10 suppressed
- ANGIOGENESIS-0.610
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- TGF_BETA_SIGNALING-0.540
- NOTCH_SIGNALING-0.490
- COAGULATION-0.480
- HYPOXIA-0.480
- CHOLESTEROL_HOMEOSTASIS-0.410
- ESTROGEN_RESPONSE_EARLY-0.400
- P53_PATHWAY-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.923 |
| 2 | TCGA-DK-AA6T-01A-11R-A39I-07 | — | — | 0.921 |
| 3 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.909 |
| 4 | C3L-00603 | — | cohortSQ1 | 0.899 |
| 5 | SRR13780255 | — | cohortSC | 0.895 |
| 6 | SRR25617851 | — | B | 0.885 |
| 7 | C3N-02728 | — | cohortMD1 | 0.884 |
| 8 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.874 |
| 9 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.869 |
| 10 | GSM6454749 | — | F | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |